From the Journals

Why a New Inhalable Lung Cancer Treatment Is So Promising


 

FROM NATURE NANOTECHNOLOGY

A New Route for ‘Powerful’ Cancer Treatment

Meanwhile, the Columbia University study showed that inhalable exosomes are a unique delivery method for IL-12 — and could help solve a major problem that’s plagued this promising cancer treatment for decades.

Called “one of the most powerful immunotherapy agents ever discovered” in a 2022 literature review, IL-12 showed serious side effects that stalled research in the 1980s , sparking an ongoing search for new delivery methods that continues today. In 2022 and 2023, Big Pharma companies including AstraZenca, Moderna, and Bristol Myers Squib reduced their involvement with IL-12 treatment research, leaving the field open to smaller biotech companies working on a variety of drug-delivery approaches that could make IL-12 safe and effective in humans.

These include injecting it directly into tumors, encasing it in various types of particles, masking the drug so it is activated only in cancer cells, and using IL-12 mRNA, which essentially turns tumor cells into IL-12–producing factories. Another IL-12 mRNA drug, from Pittsburgh-based Krystal Biotech, received a fast-track designation from the US Food and Drug Administration in February 2024 for an inhaled lung cancer treatment that packages mRNA for IL-12 and IL-2 inside an engineered virus.

And of course, there is Dr. Cheng’s inhalable treatment, culminating decades of work across three burgeoning fields.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Are Food Emulsifiers Associated With Increased Cancer Risk?
MDedge Hematology and Oncology
Lung Cancer Radiation May Up AF Risk
MDedge Hematology and Oncology
What Happens to Surgery Candidates with BHDs and Cancer?
MDedge Hematology and Oncology
FDA Removes Harmful Chemicals From Food Packaging
MDedge Hematology and Oncology
FDA Approves Amivantamab First-line Indication for NSCLC
MDedge Hematology and Oncology
Does Exercise Reduce Cancer Risk? It’s Just Not That Simple
MDedge Hematology and Oncology
Does worsening metabolic syndrome increase the risk of developing cancer?
MDedge Hematology and Oncology
ASTRO Pushes Return to Direct Supervision in RT: Needed or ‘Babysitting’?
MDedge Hematology and Oncology
Look Beyond BMI: Metabolic Factors’ Link to Cancer Explained
MDedge Hematology and Oncology
Consider These Factors in an Academic Radiation Oncology Position
MDedge Hematology and Oncology